Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients
Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients; a Randomized Double-blinded Placebo-controlled Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Leila Dargahi, PharmD/PhD
- Phone Number: +989125069930
- Email: l.dargahi@sbmu.ac.ir
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Recruiting
- Shahid Beheshti University of Medical Sciences, Shohada-e-Tajrish Hospital
-
Contact:
- Mehri Salari, MDFelloship
- Phone Number: +989124972186
- Email: mehri.salari@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women over 17 years old
- Patient with Parkinson's disease according to UKPDSBB criteria
- Patient with mild/moderate Parkinson's disease according to Hoehn and Yahr Scale (HY score = 1-3)
- Self-report or clinical diagnosis of anxiety
- Patients who have signed informed consent to participate in the study.
Exclusion Criteria:
- Pregnant and lactating women
- Parkinson's patients with onset of disease in less than 1 year
- Unstable medication for Parkinson's disease during the last two weeks
- Parkinson's patients with DBS
- Patients with other neurodegenerative diseases like multiple system atrophy (MSA), Huntington's and etc.
- Patients with major depressive disorder
- A history of using SSRIs, SNRIs, benzodiazepines and β-blockers during the last 4 weeks
- A history of using MAO inhibitors
- A history of alcohol and substance abuse
- A history of acute stress during the last 3 months
- A history of suicide
- A history of cardiovascular diseases
- A history of liver and or kidney disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Mirtazapine
Mirtazapine (15 mg), once a day, for 12 weeks
|
Mirtazapine (15 mg), once a day for 12 weeks
|
|
Placebo Comparator: Placebo
Placebo, once a day, for 12 weeks
|
Placebo, once a day, for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anxiety score
Time Frame: Baseline, and after 4 and 12 weeks of treatment
|
Anxiety score using Hamilton Anxiety Rating Scale (HAM-A)
|
Baseline, and after 4 and 12 weeks of treatment
|
|
Anxiety score
Time Frame: Baseline, and after 4 and 12 weeks of treatment
|
Parkinson Anxiety Scale (PAS) questionnaires
|
Baseline, and after 4 and 12 weeks of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depression score
Time Frame: Baseline, and after 4 and 12 weeks of treatment
|
Depression score using Hamilton Depression Rating Scale (HAM-D) questionnaire
|
Baseline, and after 4 and 12 weeks of treatment
|
|
Fatigue score
Time Frame: Baseline, and after 4 and 12 weeks of treatment
|
Fatigue score using Parkinson's Disease Fatigue Scale (PDFS) questionnaire
|
Baseline, and after 4 and 12 weeks of treatment
|
|
Sleep disorder score
Time Frame: Baseline, and after 4 and 12 weeks of treatment
|
Sleep disorder score using Parkinson's disease Sleep Scale (PDSS) questionnaire
|
Baseline, and after 4 and 12 weeks of treatment
|
|
Quality of life score
Time Frame: Baseline, and after 4 and 12 weeks of treatment
|
Quality of life score using Parkinson's Disease Quality of Life (PDQL) questionnaire
|
Baseline, and after 4 and 12 weeks of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Leila Dargahi, PharmD/PhD, Shahid Beheshti University of Medical Sciences
- Principal Investigator: Mehri Salari, MDFellowship, Shahid Beheshti University of Medical Sciences
- Study Director: Neda Valian, PhD, Shahid Beheshti University of Medical Sciences
- Study Chair: Leila Mohaghegh Shalmani, PharmD/PhD, Shahid Beheshti University of Medical Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Synucleinopathies
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Neurodegenerative Diseases
- Movement Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Anxiety Disorders
- Parkinson Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Histamine Antagonists
- Histamine Agents
- Neurotransmitter Agents
- Anti-Anxiety Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Adrenergic Agents
- Antidepressive Agents
- Serotonin 5-HT3 Receptor Antagonists
- Serotonin Antagonists
- Serotonin Agents
- Adrenergic Antagonists
- Serotonin 5-HT2 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Histamine H1 Antagonists
- Adrenergic alpha-2 Receptor Antagonists
- Mirtazapine
Other Study ID Numbers
Other Study ID Numbers
- IR.SBMU.PHNS.REC.1400.130
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.